[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332626-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332626-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-advancements-in-new-tracers-from-first-in-human-studies","Recent advancements in new tracers from first-in-human studies","","Recent advancements in positron emission tomography (PET) tracers are improving imaging of neuroinflammatory processes and neurotransmitter systems, supporting research and treatment for neurodegenerative and psychiatric disorders. Parallel progress in oncology tracers enables detailed visualization of tumor metabolic and molecular features, aiding tailored targeted therapies and response monitoring, including radiotherapy. Highlighted examples include PD-L1-, PSMA-, chemokine receptor-, HER2-, Claudin 18-, glutamine-, and ascorbic-acid-analog tracers, plus new agents for adrenal imaging, amyloidosis, and HIV infection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-advancements-in-new-tracers-from-first-in-human-studies/332626/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-advancements-in-new-tracers-from-first-in-human-studies/332626.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What imaging goals do new PET tracers support in neurology?","Question",{"text":63,"@type":64},"They support imaging of neuroinflammatory processes and neurotransmitter systems, helping advance understanding and treatment strategies for neurodegenerative and psychiatric disorders.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which oncology needs do the newer tracers address?",{"text":68,"@type":64},"They provide detailed visualization of tumor metabolic and molecular characteristics to tailor targeted therapies and monitor treatment responses, including during radiotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What kinds of non-neurological, non-oncological applications are mentioned?",{"text":72,"@type":64},"The text notes tracers for adrenal imaging, amyloidosis, and human immunodeficiency virus (HIV) infection.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332626,1790195002,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Annals of Nuclear Medicine (2024) 38:877–883  \n[https://doi.org/10.1007/s12149-024-01979-5](https://doi.org/10.1007/s12149-024-01979-5)  \nRecent advancements in new tracers from first‑in‑human studies  \nYuji Nakamoto1 · Yoshitaka Inui2 · Masatoshi Hotta3 · Hiroshi Wakabayashi4 · Hirofumi Hanaoka5  \nReceived: 16 August 2024 / Accepted: 4 September 2024 / Published online: 26 September 2024 © The Author(s) 2024  \nAbstract  \nRecent advancements in the development of positron emission tomography (PET) tracers have significantly enhanced our ability to image neuroinflammatory processes and neurotransmitter systems, which are vital for understanding and treating neurodegenerative and psychiatric disorders. Similarly, innovative tracers in oncology provide detailed images of the metabolic and molecular characteristics of tumors, which are crucial for tailoring targeted therapies and monitoring responses, including radiotherapy. Notable advancements include programmed death ligand 1 (PD-L1)-targeting agents for lung cancer, prostate-specific membrane antigen-based tracers for prostate cancer, chemokine receptor-targeting agents for hematological malignancies, human epidermal growth factor receptor 2 (HER2)-targeting tracers for various cancers, Claudin 18 based tracers for epithelial tumors, glutamine tracers for colorectal cancer, and ascorbic acid analogs for assessing cancer metabolism and therapy efficacy. Additionally, novel tracers have been developed for non-neurological and non-oncological applications, including adrenal imaging, amyloidosis, and human immunodeficiency virus (HIV) infection. This overview focuses on the newly developed tracers, particularly those used in neurology and oncology.  \nKeywords First-in-human · PET · Tracers · Radiopharmaceutical · Neurology · Oncology  \nIntroduction  \nSeveral positron emission tomography (PET) tracers have been developed in recent years. In the 1990s, the usefulness of [ 18F]-fluorodeoxyglucose (FDG) for malignant tumors was demonstrated, and it is now routinely used in several facilities. Beyond [ 18F]-FDG, new tracers that target specific receptors and molecules have significantly improved the cancer diagnosis and treatment, and are relevant for targeted therapy adaptation and response monitoring, including  \nradiotherapy. PET examinations of somatostatin receptors using [68Ga]-DOTATATE or [68Ga]-DOTATOC are widely accepted worldwide, and PSMA-based PET scans are indispensable for determining therapeutic strategies for prostate cancer in clinical settings. Fibroblast activation protein inhibitor-based PET has recently gained popularity and is expected to be widely applied [1] . Other than oncology, a PET examination with amyloid-β is being covered by insurance in Japan. Nuclear medicine imaging methods that capture specific information depend on advances in  \n* Yuji Nakamoto [ynakamo1@kuhp.kyoto-u.ac.jp](ynakamo1@kuhp.kyoto-u.ac.jp)  \nYoshitaka Inui  \n[yositaka@fujita-hu.ac.jp](yositaka@fujita-hu.ac.jp)  \nMasatoshi Hotta  \n[mhotta@hosp.ncgm.go.jp](mhotta@hosp.ncgm.go.jp)  \nHiroshi Wakabayashi  \n[wakabayashi@staff.kanazawa-u.ac.jp](wakabayashi@staff.kanazawa-u.ac.jp)  \nHirofumi Hanaoka  \n[hanaokah@hirakata.kmu.ac.jp](hanaokah@hirakata.kmu.ac.jp)  \n1 Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-Cho, Sakyo-Ku, Kyoto 606-8507, Japan  \n2 Department of Radiology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi 470-1192, Japan  \n3 Department of Radiology and Nuclear Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-Ku, Tokyo 162-8655, Japan  \n4 Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan  \n5 Division of Fundamental Technology Development, Near InfraRed Photo-ImmunoTherapy Research Institute at Kansai Medical University, 2-5-1, Shin-Machi, Hirakata 573-1010, Japan  \nradiopharmaceutical","cbCaijAsRHlGcRxI","https://ap.wps.com/l/cbCaijAsRHlGcRxI","pdf",416189,"English","# Abstract\n# Introduction\n# Innovative tracers in neurology\n## Neuroinflammation and cannabinoid-related targets\n## Imaging of cannabinoid receptors and MAGL","[{\"question\":\"What imaging goals do new PET tracers support in neurology?\",\"answer\":\"They support imaging of neuroinflammatory processes and neurotransmitter systems, helping advance understanding and treatment strategies for neurodegenerative and psychiatric disorders.\"},{\"question\":\"Which oncology needs do the newer tracers address?\",\"answer\":\"They provide detailed visualization of tumor metabolic and molecular characteristics to tailor targeted therapies and monitor treatment responses, including during radiotherapy.\"},{\"question\":\"What kinds of non-neurological, non-oncological applications are mentioned?\",\"answer\":\"The text notes tracers for adrenal imaging, amyloidosis, and human immunodeficiency virus (HIV) infection.\"}]","Recent advancements in new tracers from first-in-human studies | PDF",1789998950,18]